奎硫平治疗难治性抑郁症的辅助作用

目的：探讨奎硫平治疗难治性抑郁症的增效作用及安全性。方法：58例难治性抑郁症患者分为研究组（抗抑郁药联合奎硫平治疗）和对照组（单用抗抑郁药治疗）各29例。观察6周。于治疗前及治疗1、2、4和6周采用汉密尔顿抑郁量表（HAMD）、汉密尔顿焦虑量表（HAMA）评定疗效;以治疗中出现的症状量表（TESS）评定不良反应。结果：两组治疗后HAMD和HAMA评分均较治疗前有显著降分（P〈0.05或P〈0.001）;以研究组HAMD减分率自治疗1周起、HAMA减分率自治疗4周起均显著高于对照组（P〈0.01或P〈0.001）。两组治疗各周TESS评分差异均无统计学意义（P〉0.05）。结论：奎硫平治疗难治性抑郁症增效作用明显且安全。

Auxiliary effect of quetiapine on patients with treatment-resistant depression

Objective：To explore the efficacy and safety of quetiapine augmentation of antidepressants on treatment-resitant depression. Method：Using the random control according to the order of hospitalization,58 patients with treatment-resistant depression were assigned to quetiapine group （quetiapine plus antidepressant） and control group （antidepressant alone）.The study lasted for 6 weeks.The effects and side effects were assessed with Hamilton depression scale （HAMD）,Hamilton anxiety scale （HAMA） and treatment emergent symptom scale （TESS） respectively at baseline,week 1,2,4 and 6. Results：The total scores of HAMD and HAMA were significantly decreased after treatment in two groups （P0.05 or P0.001）.The quetiapine group had more HAMD from week one as well as HAMA from week four rate of decreation than the control group （P0.01 or P0.001）.There was no significant difference of TESS scores between two groups at each week （P0.05）. Conclusion：Quetiapine can be effective and safe in adjunctive treatment of patients with treatment-resistant depression